2026-04-22T15:15:00+00:00 2025-06-30 135381590 BDO USA 200 PARK AVE 38TH FLOOR NEW YORK NY 10166 990 2024-07-01 131933825 CANCER RESEARCH FUND OF THE DAMON RUNYON-WALTER WINCHELL FOUNDATION CANC 2124550532 55 BROADWAY 302 New York NY 10006 YUNG S LIE PHD PRESIDENT & CEO 2124550532 2026-04-22 true PAUL HAMMERSCHMIDT P01384178 2128858000 2026-04-14 2024 2025-03-06 01:10:19Z DAMON RUNYON CANCER RESEARCH FOUNDATION INC DR YUNG LIE 55 BROADWAY 302 New York NY 10006 177565031 false X WWW.DAMONRUNYON.ORG X 1947 NY ACCELERATING BREAKTHROUGHS BY FUNDING THE MOST INNOVATIVE YOUNG CANCER RESEARCHERS. 36 36 17 200 0 15903193 16245486 0 0 2228565 37892118 1427935 546003 19559693 54683607 20023840 20170035 0 0 2945531 3063164 0 0 1854773 2439313 1826419 25408684 25059618 -5848991 29623989 160511709 170380475 35205374 35526498 125306335 134853977 X TO ACCELERATE BREAKTHROUGHS BY PROVIDING TODAY'S BEST YOUNG SCIENTISTS WITH FUNDING TO PURSUE INNOVATIVE CANCER RESEARCH. THE FOUNDATION'S GOALS ARE TO IDENTIFY AND FUND THE BEST AND BRIGHTEST EARLY-CAREER SCIENTISTS IN CANCER RESEARCH; ENABLE THEM TO TAKE RISKS ON BOLD NEW IDEAS; AND ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES INTO NEW WAYS TO PREVENT OR CURE ALL FORMS OF CANCER. ITS INTERNATIONALLY RECOGNIZED AND HIGHLY COMPETITIVE GRANT PROGRAMS ARE DESIGNED TO ACHIEVE THESE GOALS. false false 8950287 8076239 0 FELLOWSHIP AWARDS: SUPPORTS THE TRAINING OF THE BRIGHTEST POSTDOCTORAL SCIENTISTS AS THEY EMBARK UPON THEIR RESEARCH CAREERS. THIS FUNDING ENABLES THEM TO BE TRAINED BY ESTABLISHED INVESTIGATORS IN LEADING RESEARCH LABORATORIES ACROSS THE COUNTRY, WHILE INDEPENDENTLY CONDUCTING LEADING-EDGE SCIENCE THAT WILL BRING NEW UNDERSTANDING AND CURES FOR CANCER. 4440990 4030412 0 CLINICAL INVESTIGATOR AWARDS: SUPPORTS EARLY CAREER PHYSICIAN-SCIENTISTS CONDUCTING PATIENT-ORIENTED RESEARCH. THE GOAL OF THIS PROGRAM IS TO INCREASE THE NUMBER OF PHYSICIANS CAPABLE OF MOVING SEAMLESSLY BETWEEN THE LABORATORY AND THE PATIENT'S BEDSIDE IN SEARCH OF BREAKTHROUGH TREATMENTS. 3514664 3194644 0 RACHLEFF INNOVATION AWARDS: SUPPORTS THE NEXT GENERATION OF EXCEPTIONALLY CREATIVE THINKERS WITH "HIGH RISK/HIGH REWARD" IDEAS THAT HAVE THE POTENTIAL TO SIGNIFICANTLY IMPACT OUR UNDERSTANDING OF AND/OR APPROACHES TO THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER, BUT LACK SUFFICIENT PRELIMINARY DATA TO OBTAIN TRADITIONAL FUNDING. 2032178 1826095 0 THE DAMON RUNYON-ST. JUDE PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD: IN PARTNERSHIP WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THIS AWARD PROVIDES FUNDING TO EARLY CAREER SCIENTISTS CONDUCTING RESEARCH WITH THE POTENTIAL TO SIGNIFICANTLY IMPACT THE PREVENTION, DIAGNOSIS, OR TREATMENT OF ONE OR MORE PEDIATRIC CANCERS. 1267965 1153426 0 QUANTITATIVE BIOLOGY FELLOWSHIP AWARDS: THIS AWARD PROGRAM IS DESIGNED TO ENCOURAGE QUANTITATIVE SCIENTISTS (TRAINED IN FIELDS SUCH AS MATHEMATICS, COMPUTER SCIENCE, PHYSICS, ENGINEERING, AND OTHERS) TO PURSUE RESEARCH CAREERS IN COMPUTATIONAL BIOLOGY UNDER THE JOINT MENTORSHIP OF LEADERS IN BOTH COMPUTATIONAL SCIENCE ("DRY LAB") AND CANCER BIOLOGY ("WET LAB"). BY INVESTING IN THIS AREA, DAMON RUNYON WILL BRING ADDITIONAL ATTENTION TO THE IMPORTANCE OF THESE SPECIALLY TRAINED SCIENTISTS FOR MAKING MEANINGFUL PROGRESS IN CANCER BIOLOGY. 1267335 1144849 0 PHYSICIAN-SCIENTIST TRAINING AWARDS: SUPPORTS AND ENCOURAGES OUTSTANDING PHYSICIANS TO PURSUE CANCER RESEARCH CAREERS BY PROVIDING THEM WITH THE OPPORTUNITY FOR A PROTECTED RESEARCH TRAINING EXPERIENCE UNDER THE MENTORSHIP OF A HIGHLY QUALIFIED AND GIFTED MENTOR. 538012 495240 0 DALE F. FREY AWARDS: AWARDS ARE GIVEN TO THE MOST OUTSTANDING FELLOWS COMPLETING THEIR FELLOWSHIP AWARD, IN THE AMOUNT OF $100,000 EACH, TO ACCELERATE THEIR RESEARCH AND CAREERS. 279698 249130 0 SPARK SCHOLARS: PROVIDES OUTSTANDING RECENT COLLEGE GRADUATES WITH THE POTENTIAL TO BECOME SCIENTIFIC LEADERS WITH A FINANCIAL STIPEND, INTENSIVE LABORATORY TRAINING, A NETWORK OF MENTORS AND PEERS, AND OTHER RESOURCES TO SUPPORT THEIR NEXT CAREER STEPS. 5385188 4868740 22291129 true true false false false false false false false true true true false true true true true false false false true false false false true false false false true true false false false false false false false false false false true false false false false false false false false false true 55 0 true 17 true false false false false false true true false false false false false false X 36 36 true false false false false false false true true false false false true true true true true true true true false false CA CO CT FL GA AL HI IL KS KY ME AK MD MA MI MN MS MO NH NJ NM NY NC OH OK OR PA AZ RI SC TN UT VA AR WA WV WI X X TRAVIS CAREY 2124550532 55 BROADWAY SUITE 302 NEW YORK NY 10006 ANDREW S RACHLEFF CHAIR (AS OF 10/15/24) 1.0 X X 0 0 0 DAVID G MARSHALL VICE CHAIR, INVESTMENTS & TREASURER (THRU 6/10/25) 1.0 X X 0 0 0 DAVID M BEIRNE VICE CHAIR, BOARD DEVELOPMENT 1.0 X X 0 0 0 DEBORAH J COLEMAN SECRETARY (AS OF 6/10/25) 1.0 X X 0 0 0 LAURENCE W COHEN TREASURER (AS OF 10/15/24) 1.0 X X 0 0 0 MICHAEL L GORDON VICE CHAIR, BOARD DEVELOPMENT (THRU 10/15/24) 1.0 X X 0 0 0 SANFORD W MORHOUSE ESQ VICE CHAIR, AUDIT & SECRETARY (THRU 6/10/25) 1.0 X X 0 0 0 WILLIAM G KAELIN JR MD VICE CHAIR, SCIENTIFIC PROGRAMS 1.0 X X 0 0 0 ADAM R SCHWARTZ DIRECTOR 1.0 X 0 0 0 AMOOLYA SINGH PHD DIRECTOR 1.0 X 0 0 0 BUCK FRENCH DIRECTOR 1.0 X 0 0 0 CARLOS L ARTEAGA MD DIRECTOR 1.0 X 0 0 0 CYNTHIA SULZBERGER DIRECTOR 1.0 X 0 0 0 DAVID A GORDON PHD DIRECTOR 1.0 X 0 0 0 ELAINE V FUCHS PHD DIRECTOR 1.0 X 0 0 0 ERICA EVANS GIOFFRE DIRECTOR 1.0 X 0 0 0 GABRIELLE LAYTON PHD DIRECTOR 1.0 X 0 0 0 GARY E ERLBAUM DIRECTOR 1.0 X 0 0 0 GERALD M MARSHALL DIRECTOR 1.0 X 0 0 0 JAMES WELLS PHD DIRECTOR 1.0 X 0 0 0 JOHN H MYERS DIRECTOR (THRU 10/15/24) 1.0 X 0 0 0 JOSEPH PEARLBERG MD PHD DIRECTOR 1.0 X 0 0 0 JUDY SWANSON DIRECTOR 1.0 X 0 0 0 KAREN D SEITZ DIRECTOR (THRU 10/15/24) 1.0 X 0 0 0 LEVI A GARRAWAY MD PHD DIRECTOR 1.0 X 0 0 0 LORI J PIERCE MD DIRECTOR 1.0 X 0 0 0 MELISSA L COHN DIRECTOR 1.0 X 0 0 0 MICHAEL V SEIDEN MD PHD DIRECTOR 1.0 X 0 0 0 MORANA JOVAN-EMBIRICOS PHD DIRECTOR 1.0 X 0 0 0 NANCY SIMONIAN MD DIRECTOR 1.0 X 0 0 0 NOAH KNAUF DIRECTOR 1.0 X 0 0 0 PETER VAN CAMP DIRECTOR 1.0 X 0 0 0 RICHARD B GAYNOR MD DIRECTOR 1.0 X 0 0 0 RICHARD HOFFMAN DIRECTOR 1.0 X 0 0 0 RICHARD J O'REILLY MD DIRECTOR 1.0 X 0 0 0 RICHARD W MEIER DIRECTOR 1.0 X 0 0 0 ROBYN COLES DIRECTOR 1.0 X 0 0 0 SCOTT GREENSTEIN DIRECTOR 1.0 X 0 0 0 STEVEN A KANDARIAN DIRECTOR 1.0 X 0 0 0 STEVEN J BURAKOFF MD DIRECTOR (THRU 10/15/24) 1.0 X 0 0 0 TODD R GOLUB MD DIRECTOR 1.0 X 0 0 0 YUNG S LIE PHD PRESIDENT & CEO 40.0 X 592380 0 59913 CLARE CAHILL CHIEF ADMINISTRATIVE OFFICER 40.0 X 253185 0 36955 ELYSE HOFFMANN SENIOR DIRECTOR OF STRATEGIC PARTNERSHIP 40.0 X 199837 0 39199 KIMBERLY KUBERT DIRECTOR OF SPECIAL EVENTS 40.0 X 211585 0 35757 MEGAN ALLEN PHD SCIENTIFIC DIRECTOR 40.0 X 143407 0 24343 MEGHAN MCCURDY DIRECTOR OF COMMUNICATIONS & MARKETING 40.0 X 157037 0 43527 1557431 0 239694 9 false true false CRAFT & COMMERCE 714 N HYE AVENUE ORLANDO FL 32803 MEDIA SERVICES 250375 JP MORGAN 270 PARK AVENUE NEW YORK NY 10017 INVESTMENT ADVISORY 110736 CAREY & CO 658 PECONIC AVENUE WEST BABYLON NY 11704 ACCOUNTING SERVICES 109520 3 1119076 15126410 1186150 16245486 0 0 0 0 0 3321709 3321709 391793 391793 0 0 157141699 122571290 34570409 0 34570409 34570409 205580 1119076 310134 -104554 -104554 TRUST INCOME 525990 258764 258764 0 0 0 0 258764 54683607 0 0 38438121 20170035 20170035 666526 282653 122898 260975 1756670 744949 323905 687816 180836 76687 33344 70805 312260 132420 57576 122264 146872 62284 27081 57507 22829 9681 4209 8939 229412 97287 42300 89825 110736 0 110736 0 173916 73752 32068 68096 106926 0 34233 72693 49234 20879 9078 19277 94635 40132 17449 37054 364829 154713 67269 142847 149635 0 0 149635 129034 120805 2634 5595 24196 10261 4461 9474 43763 18559 8069 17135 ADVISORY COMMITTEE SERVICE 238301 238301 0 0 AWARD RELATED 56786 24081 10471 22234 MISCELLANEOUS EXPENSES 32187 13650 5935 12602 0 0 0 0 25059618 22291129 913716 1854773 148992 148351 16595615 3628083 7056004 6997256 244198 137812 0 0 167213 197564 860426 642829 188469 217597 44513296 136850784 82691491 13103967 0 8906431 9099061 160511709 170380475 428342 431331 32112667 33667472 897211 0 1767154 1427695 35205374 35526498 X 106512416 114368896 18793919 20485081 125306335 134853977 160511709 170380475 X 29623989 -20088670 12323 X false true true false X 15008268 8036836 9155827 15903193 16245486 64349610 0 0 15008268 8036836 9155827 15903193 16245486 64349610 1820247 62529363 2945775 3424747 3076164 4957917 3972266 18376869 0 58174 364423 324597 337329 205580 1290103 84016582 0 0.74425 0.6764 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - SPECIAL EVENT INCOME, COLUMN A - 2293.0, COLUMN B - 357797.0, COLUMN C - 316581.0, COLUMN D - 315790.0, COLUMN E - 205580.0, COLUMN F - 1198041.0; DESCRIPTION - MISCELLANEOUS INCOME, COLUMN A - 55881.0, COLUMN B - 6626.0, COLUMN C - 8016.0, COLUMN D - 21539.0, COLUMN E - 0.0, COLUMN F - 92062.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 140568457 3393582 17803448 11700000 0 110736 149954751 126338483 3729706 18139854 7500000 0 139586 140568457 120646027 2779866 14412590 11500000 0 0 126338483 142590768 2202136 -17472677 6500000 0 174200 120646027 115139591 6398765 33243829 11000000 676757 514660 142590768 0.9203 0.0797 0.0 false false 376804 293763 83041 245006 110450 134556 238616 238616 0 217597 Closely-held equity interests Financial derivatives LIMITED PARTNERSHIPS 13103967 F 13103967 AMOUNT HELD IN TRUST BY OTHERS 7933113 OPERATING LEASE RIGHT-OF-USE ASSET 1165948 9099061 Federal Income Taxes OPERATING LEASE LIABILITY 1427695 1427695 X 35455581 -20088670 354000 465249 -19269421 54725002 110736 -152131 -41395 54683607 25907939 354000 605057 959057 24948882 110736 0 110736 25059618 Schedule D, Part V, Line 4 Intended uses of endowment funds ENDOWMENT ASSETS ARE REPRESENTED BY AVAILABLE FUNDS ALLOCATED BY THE FOUNDATION FOR LONG-TERM INVESTMENT, AND FUNDS RECEIVED FROM DONORS FOR FUNDING OF SCIENTIFIC AWARDS THAT ARE INCLUDED IN NET ASSETS WITH DONOR RESTRICTIONS. THE INCOME GENERATED BY THESE FUNDS CAN BE USED FOR UNRESTRICTED PURPOSES. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE FOUNDATION IS INCORPORATED AS A NEW YORK NONPROFIT CORPORATION AND HAS BEEN RECOGNIZED BY THE INTERNAL REVENUE SERVICE (IRS) AS EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE (IRC) SECTION 501(A) AS AN ORGANIZATION DESCRIBED IN IRC SECTION 501(C) (3); QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER IRC SECTIONS 107(B)(1)(A)(VI) AND (VIII); AND HAS BEEN DETERMINED NOT TO BE A PRIVATE FOUNDATION UNDER SECTION 509(A)(1) AND (3). THE FOUNDATION IS ANNUALLY REQUIRED TO FILE A RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX (FORM 990) WITH THE IRS. IN ADDITION, THE FOUNDATION IS SUBJECT TO INCOME TAX ON NET INCOME THAT IS DERIVED FROM BUSINESS ACTIVITIES THAT ARE UNRELATED TO ITS EXEMPT PURPOSES. FOR THE YEARS ENDED JUNE 30, 2025 AND 2024, THE FOUNDATION DID NOT INCUR ANY UNRELATED BUSINESS INCOME TAX AND HAS NOT FILED AN EXEMPT ORGANIZATION BUSINESS INCOME TAX RETURN (FORM 990-T) WITH THE IRS. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 CHANGE IN VALUE OF PERPETUAL TRUSTS - 339857 CHANGE IN VALUE OF CHARITABLE REMAINDER TRUSTS - 125392 Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements SPECIAL EVENTS EXPENSES NETTED AGAINST SPECIAL EVENTS - -152131 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 SPECIAL EVENTS EXPENSES NETTED AGAINST SPECIAL EVENTS - 152131 UNCOLLECTIBLE CHARITABLE CONTRIBUTIONS - 452926 Central America and the Caribbean 0 0 Investments 13103542 0 0 0 0 0 0 13103542 0 13103542 false false false false false false DAMON RUNYON BREAKFAST 907408 886088 21320 0 0 35730 11910 21268 9616 THEATRE BOX OFFICE 264654 124005 140649 0 0 0 0 142562 15441 8 152594 108983 43611 0 0 10234 32245 13760 17368 1324656 1119076 205580 0 0 45964 44155 177590 42425 310134 -104554 true DAMON RUNYON FELLOWSHIP AWARDS 29 8076239 DAMON RUNYON CLINICAL INVESTIGATOR AWARDS & CONTINUATION GRANTS 8 4030412 DAMON RUNYON RACHLEFF INNOVATION AWARDS 8 3194644 DAMONRUNYON-ST. JUDE PEDIATRIC CANCER FELLOWSHIP AWARDS 7 1826095 DAMON RUNYON QUANTATATIVE BIOLOGY AWARDS 3 1153426 DAMON RUNYON PHYSICIAN SCIENTISTS AWARDS 3 1144849 DAMON RUNYON DALE FREY AWARDS 5 495240 DAMON RUNYON SPARK SCHOLAR AWARDS 4 249130 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds THE FOUNDATION MAINTAINS CONTEMPORANEOUS RECORDS SUBSTANTIATING GRANT AMOUNTS, GRANTEE ELIGIBILITY, AND SELECTION CRITERIA, INCLUDING APPLICATIONS AND SUPPORTING DOCUMENTS, INSTITUTIONAL ELIGIBILITY CONFIRMATIONS/CERTIFICATIONS, PEER-REVIEW SCORING AND WRITTEN EVALUATIONS, CONFLICT-OF-INTEREST AND RECUSAL DOCUMENTATION, AWARD APPROVALS, EXECUTED AWARD AGREEMENTS, PAYMENT SCHEDULES, AND GENERAL LEDGER SUPPORT. TO MONITOR THE USE OF GRANT FUNDS IN THE UNITED STATES, AWARDS ARE MADE TO SPONSORING INSTITUTIONS ON BEHALF OF INDIVIDUAL AWARDEES PURSUANT TO STANDARD WRITTEN AWARD TERMS. FUNDS MUST BE MAINTAINED IN A SEPARATE INSTITUTIONAL ACCOUNT BY AWARD, USED ONLY FOR ALLOWABLE COSTS, AND ARE SUBJECT TO REPORTING AND REVIEW. THE FOUNDATION REQUIRES PERIODIC SCIENTIFIC/PROGRESS REPORTS AND ANNUAL FINANCIAL REPORTS; CONTINUED FUNDING AND INSTALLMENT PAYMENTS ARE CONTINGENT ON TIMELY SUBMISSION AND SATISFACTORY REVIEW OF REQUIRED REPORTS. CHANGES IN SCOPE, INSTITUTION, OR OTHER KEY PROJECT TERMS REQUIRE PRIOR WRITTEN FOUNDATION APPROVAL. THE FOUNDATION PERFORMS PERIODIC FINANCIAL REVIEW/TESTING OF REPORTED EXPENDITURES FOR ALLOWABILITY AND COMPLIANCE. UNSPENT OR IMPROPERLY USED FUNDS MUST BE RETURNED, AND NONCOMPLIANCE MAY RESULT IN CORRECTIVE ACTION, SUSPENSION OF PAYMENTS, TERMINATION, AND/OR IMPACT FUTURE ELIGIBILITY. X X X X X false false false false false false false true false YUNG S LIE PHD PRESIDENT & CEO 507380 0 85000 0 0 0 34500 0 25413 0 652293 0 0 0 CLARE CAHILL CHIEF ADMINISTRATIVE OFFICER 238185 0 15000 0 0 0 23360 0 13595 0 290140 0 0 0 KIMBERLY KUBERT DIRECTOR OF SPECIAL EVENTS 196585 0 15000 0 0 0 19280 0 16477 0 247342 0 0 0 ELYSE HOFFMANN SENIOR DIRECTOR OF STRATEGIC PARTNERSHIP 184837 0 15000 0 0 0 0 0 39199 0 239036 0 0 0 MEGHAN MCCURDY DIRECTOR OF COMMUNICATIONS & MARKETING 157037 0 0 0 0 0 15770 0 27757 0 200564 0 0 0 MEGAN ALLEN PHD SCIENTIFIC DIRECTOR 143407 0 0 0 0 0 7866 0 16477 0 167750 0 0 0 Schedule J, Part I, Line 7 Non-fixed payments THE FOLLOWING INDIVIDUALS, LISTED ON PART VII, RECEIVED A NON-FIXED PAYMENT IN THE FORM OF A BONUS DURING THE 2024 YEAR: YUNG LIE - $85,000 CLARE CAHILL - $15,000 ELSYE HOFFMANN- $15,000 KIM KUBERT - $15,000 19 1186150 Other - MARKET QUOTATION 0 false false false Schedule M, Part I THE NUMBER OF CONTRIBUTIONS FOR SECURITIES IS THE NUMBER OF SEPARATE DONATIONS, NOT THE NUMBER OF SHARES OF STOCK. Form 990, Part III, Line 4d Description of other program services (Expenses $ 2,032,178 including grants of $ 1,826,095)(Revenue $ 0) THE DAMON RUNYON-ST. JUDE PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD: IN PARTNERSHIP WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THIS AWARD PROVIDES FUNDING TO EARLY CAREER SCIENTISTS CONDUCTING RESEARCH WITH THE POTENTIAL TO SIGNIFICANTLY IMPACT THE PREVENTION, DIAGNOSIS, OR TREATMENT OF ONE OR MORE PEDIATRIC CANCERS. Form 990, Part III, Line 4d Description of other program services (Expenses $ 1,267,965 including grants of $ 1,153,426)(Revenue $ 0) QUANTITATIVE BIOLOGY FELLOWSHIP AWARDS: THIS AWARD PROGRAM IS DESIGNED TO ENCOURAGE QUANTITATIVE SCIENTISTS (TRAINED IN FIELDS SUCH AS MATHEMATICS, COMPUTER SCIENCE, PHYSICS, ENGINEERING, AND OTHERS) TO PURSUE RESEARCH CAREERS IN COMPUTATIONAL BIOLOGY UNDER THE JOINT MENTORSHIP OF LEADERS IN BOTH COMPUTATIONAL SCIENCE ("DRY LAB") AND CANCER BIOLOGY ("WET LAB"). BY INVESTING IN THIS AREA, DAMON RUNYON WILL BRING ADDITIONAL ATTENTION TO THE IMPORTANCE OF THESE SPECIALLY TRAINED SCIENTISTS FOR MAKING MEANINGFUL PROGRESS IN CANCER BIOLOGY. Form 990, Part III, Line 4d Description of other program services (Expenses $ 1,267,335 including grants of $ 1,144,849)(Revenue $ 0) PHYSICIAN-SCIENTIST TRAINING AWARDS: SUPPORTS AND ENCOURAGES OUTSTANDING PHYSICIANS TO PURSUE CANCER RESEARCH CAREERS BY PROVIDING THEM WITH THE OPPORTUNITY FOR A PROTECTED RESEARCH TRAINING EXPERIENCE UNDER THE MENTORSHIP OF A HIGHLY QUALIFIED AND GIFTED MENTOR. Form 990, Part III, Line 4d Description of other program services (Expenses $ 538,012 including grants of $ 495,240)(Revenue $ 0) DALE F. FREY AWARDS: AWARDS ARE GIVEN TO THE MOST OUTSTANDING FELLOWS COMPLETING THEIR FELLOWSHIP AWARD, IN THE AMOUNT OF $100,000 EACH, TO ACCELERATE THEIR RESEARCH AND CAREERS. Form 990, Part III, Line 4d Description of other program services (Expenses $ 279,698 including grants of $ 249,130)(Revenue $ 0) SPARK SCHOLARS: PROVIDES OUTSTANDING RECENT COLLEGE GRADUATES WITH THE POTENTIAL TO BECOME SCIENTIFIC LEADERS WITH A FINANCIAL STIPEND, INTENSIVE LABORATORY TRAINING, A NETWORK OF MENTORS AND PEERS, AND OTHER RESOURCES TO SUPPORT THEIR NEXT CAREER STEPS. Form 990, Part VI, Line 2 Family/business relationships amongst interested persons DAVID MARSHALL AND GERALD MARSHALL - Family relationship, MICHAEL GORDON AND DAVID GORDON - Family relationship Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS REVIEWED FIRST BY THE PRESIDENT & CEO AND THE FINANCE CONSULTANT. IT IS THEN PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW AND APPROVAL. IT IS SUBSEQUENTLY PROVIDED TO THE BOARD OF DIRECTORS FOR INFORMATION BEFORE IT IS FILED WITH THE IRS AND IS THEN REVIEWED AT THE NEXT BOARD MEETING. Form 990, Part VI, Line 12c Conflict of interest policy THE CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS, AS WELL AS ALL MEMBERS OF THE STAFF AND THOSE SERVING ON AWARD COMMITTEES. ON AN ANNUAL BASIS, BOARD MEMBERS AND SENIOR STAFF ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST QUESTIONNAIRE, NOTING ANY POTENTIAL CONFLICTS OF INTEREST. STAFF MEMBERS AND AWARD COMMITTEE MEMBERS SIGN THIS QUESTIONNAIRE PRIOR TO COMMENCING EMPLOYMENT OR SERVING ON THE COMMITTEE, RESPECTIVELY. IT SHALL BE THE CONTINUING DUTY OF EACH PERSON COMPLETING THE QUESTIONNAIRE TO ADVISE THE BOARD OF DIRECTORS, THROUGH THE SECRETARY, PROMPTLY OF ANY CIRCUMSTANCES THAT WOULD ALTER THE ANSWER TO ANY QUESTION ON HIS OR HER COMPLETED QUESTIONNAIRE. POTENTIAL CONFLICTS OF INTEREST ARE THEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. ANY INDIVIDUAL DETERMINED TO HAVE A CONFLICT OF INTEREST, OR APPEARANCE OF A CONFLICT OF INTEREST, WITH RESPECT TO ANY MATTER, SHALL NOT VOTE OR PARTICIPATE IN OR BE PRESENT AT ANY DELIBERATIONS OR USE HIS OR HER PERSONAL INFLUENCE IN SUCH MATTER. Form 990, Part VI, Line 15a Process to establish compensation of top management official COMPENSATION OF THE PRESIDENT & CHIEF EXECUTIVE OFFICER AND SENIOR STAFF IS DETERMINED ANNUALLY AFTER REVIEW OF THEIR PERFORMANCE BY THE CHAIRMAN OF THE BOARD. THE CHAIRMAN OF THE BOARD IS SUPPORTED IN THIS PROCESS BY A COMPENSATION COMMITTEE WHICH REVIEWS THE PERFORMANCE REVIEWS AND COMPARABILITY DATA. THE BOARD CHAIR THEN PRESENTS THE REVIEW AND RECOMMENDATION ON COMPENSATION TO THE EXECUTIVE COMMITTEE OF THE BOARD FOR REVIEW AND APPROVAL. IT IS THEN REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS IN EXECUTIVE SESSION AT ITS NEXT MEETING. IN SEPTEMBER OF 2022, AN OUTSIDE COMPENSATION CONSULTANT WAS ENGAGED TO CONDUCT A COMPENSATION STUDY, WHICH INCLUDED A FORMAL REVIEW OF KEY POSITIONS. Form 990, Part VI, Line 15b Process to establish compensation of other employees COMPENSATION OF THE PRESIDENT & CHIEF EXECUTIVE OFFICER AND SENIOR STAFF IS DETERMINED ANNUALLY AFTER REVIEW OF THEIR PERFORMANCE BY THE CHAIRMAN OF THE BOARD. THE CHAIRMAN OF THE BOARD IS SUPPORTED IN THIS PROCESS BY A COMPENSATION COMMITTEE WHICH REVIEWS THE PERFORMANCE REVIEWS AND COMPARABILITY DATA. THE BOARD CHAIR THEN PRESENTS THE REVIEW AND RECOMMENDATION ON COMPENSATION TO THE EXECUTIVE COMMITTEE OF THE BOARD FOR REVIEW AND APPROVAL. IT IS THEN REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS IN EXECUTIVE SESSION AT ITS NEXT MEETING. IN SEPTEMBER OF 2022, AN OUTSIDE COMPENSATION CONSULTANT WAS ENGAGED TO CONDUCT A COMPENSATION STUDY, WHICH INCLUDED A FORMAL REVIEW OF KEY POSITIONS. Form 990, Part VI, Line 19 Required documents available to the public THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). THE FINANCIAL STATEMENTS ARE ALSO POSTED ON THE ORGANIZATION'S WEBSITE. Form 990, Part VII, Section A THE ORGANIZATION, IN A FULL TRANSPARENCY POSTURE TO REPORTING, IS REPORTING ALL BENEFITS IN FULL IN PART VII, COLUMN F AND NOT APPLYING THE $10,000 PER ITEM EXCEPTION FOR CERTAIN BENEFITS. Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGE IN VALUE OF PERPETUAL TRUSTS - 339857; CHANGE IN VALUE OF CHARITABLE REMAINDER TRUSTS - 125392; UNCOLLECTIBLE CHARITABLE CONTRIBUTIONS - -452926; Total - 12323;